Sibrafiban

Source: Wikipedia, the free encyclopedia.
Sibrafiban
Identifiers
  • [Z]-(S)-[[1-[2-[[4-(amino-hydroxyiminomethyl)-benzoyl]amino]-1-oxopropyl]-4-piperidinyl]oxyl]-acetic ethyl ester
JSmol)
  • CCOC(=O)COC1CCN(CC1)C(=O)[C@H](C)NC(=O)c2ccc(cc2)C(=N)NO
  • InChI=1S/C20H28N4O6/c1-3-29-17(25)12-30-16-8-10-24(11-9-16)20(27)13(2)22-19(26)15-6-4-14(5-7-15)18(21)23-28/h4-7,13,16,28H,3,8-12H2,1-2H3,(H2,21,23)(H,22,26)/t13-/m0/s1
  • Key:WBNUCLPUOSXSNJ-ZDUSSCGKSA-N

Sibrafiban (Ro 48–3657, proposed brand name Xubix) is the double

Hoffmann-La Roche announced that the preliminary results from Phase III clinical trials had not shown that sibrafiban was better than aspirin
in preventing recurrent ischemic events in patients with acute coronary syndrome. The development of sibrafiban was terminated.

See also

References

  1. S2CID 263996772
    .


drug article relating to the blood and blood forming organs is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Sibrafiban&oldid=1199126897"